Mycophenolate Mofetil Dosing and Monitoring in Post‑Liver Transplant Patients

Dose Initiation and Escalation

• Begin MMF at 500 mg twice daily and increase by 500 mg each week until the target dose of 1000 mg twice daily (2 g total daily) is reached; this gradual escalation reduces gastrointestinal adverse effects and permits tolerance assessment. 1

Standard Immunosuppression Regimens

• The conventional regimen for liver transplant recipients combines mycophenolate mofetil 1.5 g twice daily (3 g total daily) with tacrolimus. [2][3]

Drug Interaction and Safety Considerations

• Substituting generic MMF formulations without additional monitoring is discouraged because bio‑equivalence uncertainties may increase rejection risk. [2][3]
• Concomitant use of allopurinol should be avoided, as it can raise antimetabolite levels to toxic concentrations. 3
• Co‑administration of non‑steroidal anti‑inflammatory drugs (NSAIDs) should be limited because they potentiate calcineurin‑inhibitor‑related nephrotoxicity. 3

Monitoring Protocols

• When patients develop gastrointestinal intolerance, measure plasma mycophenolic acid (MPA) concentrations to determine whether MMF is the causative agent. 4

Management of Gastrointestinal Toxicity

• If diarrhea or other GI symptoms occur, temporarily discontinue MMF or reduce the dose, and obtain plasma MPA levels to confirm causality. 4
• Consider switching to an enteric‑coated mycophenolate sodium formulation; evidence in liver transplantation remains limited. 5

Pregnancy Contraindication

• Mycophenolate mofetil is contraindicated in pregnancy due to teratogenic risk; it should be stopped 6–12 weeks before planned conception. 6